Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P62714

UPID:
PP2AB_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P62714; D3DSV4; P11082; Q6FHK5

BACKGROUND:
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform, with UniProt accession P62714, is a crucial enzyme in the PP2A complex. This enzyme is responsible for the dephosphorylation of serine and threonine residues in target proteins, thereby influencing a multitude of signaling pathways and cellular functions. Its regulatory capacity spans across various enzymes and pathways, highlighting its significance in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform's functions offers a promising avenue for therapeutic intervention. Given its central role in regulating key cellular processes, targeting this protein could lead to innovative treatments for diseases where these pathways are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.